| Ytd | -97.70% | |
| 1y | -97.70% |
| Open | 0.52 | Prev Close | 0.51 | Low | 0.52 | High | 0.55 | Mkt Cap | 3.09M |
| Vol | 103.71K | Avg Vol | 799.85K | EPS | -0.53 | P/E | -1.03 | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.83 | 200-d Avg | 1.98 | 1yr Est | 0.00 |
AIDX News
Shares of Super Micro Computer Inc (NASDAQ: SMCI) rose after reporting record backlog of $60B+ in or
Company Outlines Strategy to Position OneTest™ as the First Affordable, Multi-Cancer Early Detection
Inaugural Session to be Held Wednesday, July 1, 2026, at 12:00 p.m. ET Recurring Forum Intended to I
Tower Semiconductor (TSEM) jumped 4.7% in pre-market trading after announcing a multi-year supply ag
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Rev
Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies
State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Begin
GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an
Patented Algorithm Designed to Help Identify Otherwise Dangerous Prostate Tumors Earlier Using Repea
Healwell AI Inc. (AIDX:CA) Q1 2026 Earnings Call Transcript
Joint Release Expands 20/20 BioLabs' Testing Solutions Across Evexia's Network of ~40,000 Functional
Full Year 2025 Revenue of $2.0 Million, up 17% from 2024 Gross Profit Increased 68% in FY 2025 and G
State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Det
Inflammatory Biomarker Tracking Predicted to Enhance Response to 3-D Bio-Printed Therapies Expands
